Mobile Trading

VENUS REMEDIES LTD.

NSE : VENUSREMBSE : 526953ISIN CODE : INE411B01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE455.00-4.9 (-1.07 %)
PREV CLOSE ( ) 459.90
OPEN PRICE ( ) 445.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 752
TODAY'S LOW / HIGH ( )445.50 462.00
52 WK LOW / HIGH ( )272.2 474.8
Select year
ParticularsMar2024Mar2023Mar2022Mar2021Mar2020
Operational & Financial Ratios
   Earnings Per Share (Rs)21.3119.8730.4750.04-8.10
   CEPS(Rs)41.1044.0455.5578.6317.84
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)364.74344.38329.50313.18262.01
   Tax Rate(%)36.1829.96-11.85-27.21-24.44
Margin Ratios
   Core EBITDA Margin(%)9.9110.8110.359.8112.03
   EBIT Margin(%)7.446.856.1511.231.56
   Pre Tax Margin(%)7.426.836.078.86-2.37
   PAT Margin (%)4.744.786.7911.27-2.95
   Cash Profit Margin (%)9.1310.6012.3717.706.49
Performance Ratios
   ROA(%)4.644.507.1810.30-1.45
   ROE(%)6.015.909.8517.40-3.05
   ROCE(%)8.677.727.8912.370.90
   Asset Turnover(x)0.980.941.060.910.49
   Sales/Fixed Asset(x)0.980.910.980.880.51
   Working Capital/Sales(x)2.152.313.244.014.89
Efficiency Ratios
   Fixed Capital/Sales(x)1.021.091.021.131.96
   Receivable days47.6937.8721.4820.8936.97
   Inventory Days73.3280.6874.6986.94152.66
   Payable days48.8755.6957.3157.8676.11
Valuation Parameters
   PER(x)15.318.158.825.490.00
   PCE(x)7.943.684.843.491.26
   Price/Book(x)0.890.470.820.880.09
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)0.680.370.590.650.73
   EV/Core EBITDA(x)5.752.905.004.895.34
   EV/EBIT(x)9.155.379.545.8346.42
   EV/CE(x)0.770.410.610.650.38
   M Cap / Sales0.730.390.600.620.08
Growth Ratio
   Net Sales Growth(%)8.27-7.449.5061.535.42
   Core EBITDA Growth(%)1.19-0.11-4.0759.1419.44
   EBIT Growth(%)17.583.14-40.091061.31222.71
   PAT Growth(%)7.25-34.77-34.07717.7065.01
   EPS Growth(%)7.25-34.77-39.12717.7065.01
Financial Stability Ratios
   Total Debt/Equity(x)0.080.090.100.130.68
   Current Ratio(x)4.533.913.002.401.31
   Quick Ratio(x)2.992.461.641.170.68
   Interest Cover(x)477.45322.4476.694.730.40
   Total Debt/Mcap(x)0.090.200.120.157.94

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER
© 2018 Ratnakar Securities Pvt. Ltd. All rights reserved.
Designed, Developed & Content Powered by  Accord Fintech Pvt. Ltd.
CLOSE X

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal (link:https://scores.gov.in)
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.